Implementation of Mass Cytometry as a Tool for Mechanism of Action Studies in Inflammatory Bowel Disease-Reference-Cited by-同舟云学术

Implementation of Mass Cytometry as a Tool for Mechanism of Action Studies in Inflammatory Bowel Disease

Published:2018-06-08 Issue:11 Volume:24 Page:2366-2376
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Tyler Christopher J¹²,Pérez-Jeldres Tamara¹²³,Ehinger Erik⁴,Capaldo Brian⁵,Karuppuchamy Thangaraj¹²,Boyer Joshua D¹²,Patel Derek²,Dulai Parambir¹²,Boland Brigid S¹,Lannigan Joanne⁵,Eckmann Lars¹,Ernst Peter B⁶⁷,Sandborn William J²,Ho Samuel B¹²,Rivera-Nieves Jesús¹²

Affiliation:

1. Inflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, California

2. VA San Diego Healthcare System, San Diego, California

3. Universidad Catolica de Chile, Santiago, Chile

4. Flow Cytometry Core Facility, La Jolla Institute of Allergy and Immunology, La Jolla, California

5. Flow Cytometry Core Facility, University of Virginia, Charlottesville, Virginia

6. Division of Comparative Pathology, Department of Pathology, University of California San Diego, La Jolla, California

7. Chiba University–UC San Diego Program in Mucosal Immunology, Allergy and Vaccines, San Diego, California

Funder

National Institutes of Health

VA merit

Shared Instrumentation Grant (SIG) Program (S10)

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

http://academic.oup.com/ibdjournal/article-pdf/24/11/2366/26034863/izy214.pdf

Reference35 articles.

1. Inflammatory bowel disease: an expanding global health problem;M’Koma;Clin Med Insights Gastroenterol,2013

2. Drug development in IBD: from novel target identification to early clinical trials;Danese;Gut,2016

3. Frontiers in drug research and development for inflammatory bowel disease;Currò;Front Pharmacol,2017

4. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease;Sandborn;Gastroenterology,2002

5. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis;D’Haens;Gastroenterology,2007

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Opening the doors of precision medicine: novel tools to assess intestinal barrier in inflammatory bowel disease and colitis-associated neoplasia;Gut;2024-06-08

2. Transcriptional Behavior of Regulatory T Cells Predicts IBD Patient Responses to Vedolizumab Therapy;Inflammatory Bowel Diseases;2022-08-22

3. Antibody secreting cells are critically dependent on integrin α4β7/MAdCAM-1 for intestinal recruitment and control of the microbiota during chronic colitis;Mucosal Immunology;2021-08-25

4. Use of Single-Cell -Omic Technologies to Study the Gastrointestinal Tract and Diseases, From Single Cell Identities to Patient Features;Gastroenterology;2020-08

5. Inherent Immune Cell Variation Within Colonic Segments Presents Challenges for Clinical Trial Design;Journal of Crohn's and Colitis;2020-04-02